PDCD1 and neoplasm: Although NLRP3 inhibitors have worked to reduce inflammation, their combination with other therapeutic methods, such as immune checkpoint inhibitors, such as anti-PD-1, may enhance their anti-tumor effects by modulating the TME [186,187].